DXCMDexCom, Inc.

Filed with the SEC on October 29, 2026 | Form 8-K (Items 2.02, 8.01, 9.01) | Current Price: $84.33 (+5.50%)

---

What Happened

DexCom, Inc. filed an 8-K with the SEC on October 29, 2026, disclosing its financial results for the third quarter of fiscal year 2026. Revenue from contracts with customers reached $3.40 billion for Q3 FY2026, a figure that stands in stark contrast to the $497.5 million reported in Q3 FY2018 — underscoring how dramatically the company's top line has scaled over eight years. Net income came in at $569.0 million, with diluted earnings per share of $1.42, and operating income of $588.8 million, signaling that profitability has kept pace with revenue growth. The disclosure is material because it provides the market with a concrete, auditable look at DexCom's operating performance at a scale that was previously difficult to fully model.

---

Why It Matters

For investors tracking DexCom's trajectory, these numbers tell a clear story:

• Revenue scale: $3.40 billion in a single quarter represents a business that has effectively transformed itself from a niche medical device maker into a large-cap healthcare growth franchise.
• Profitability quality: Operating income of $588.8 million against revenues of $3.40 billion implies a strong operating margin profile, suggesting the company is not sacrificing profitability to chase growth.
• Earnings power: Basic EPS of $1.45 and diluted EPS of $1.42 reflect meaningful per-share earnings generation, which is relevant for investors assessing intrinsic value.
• Market reaction: Shares are up 5.50% to $84.33 on the day of this report, a move consistent with results that exceeded the market's prior expectations.

This follows StockWatch's initiating coverage published on October 21, 2026, which had already identified DexCom as a company worth close attention — and these reported figures appear to validate the underlying thesis that the business is executing at a high level.

---

Analysis

The headline numbers here are hard to dismiss. A quarterly revenue run rate of $3.40 billion annualizes to well over $13 billion, and the company is generating that revenue with operating income comfortably above half a billion dollars in a single quarter. What is particularly notable is that operating income of $588.8 million actually exceeded net income of $569.0 million on a reported basis — a relationship that can reflect favorable below-the-line items or tax dynamics, and is worth examining in the full financial statements attached to the filing.

The Q3 FY2018 revenue comparison included in the XBRL data ($497.5 million) serves as an important historical anchor: DexCom has grown quarterly revenues by nearly 7x in roughly eight years, a compounding rate that is exceptional even within the high-growth medtech sector.

Key things to watch going forward:

• Full-year FY2026 revenue trajectory: Does Q3 represent a sustained run rate or a seasonal peak?
• Margin sustainability: Can operating margins be maintained as the business scales further, particularly in international markets?
• Competitive dynamics: The continuous glucose monitoring (CGM) space has attracted significant new entrants; how DexCom is managing market share will be central to any forward view.
• Cash flow disclosure: The 8-K filing references Exhibit 9.01 alongside the earnings items, suggesting additional financial schedules — investors should review the complete filing.

The 5.50% intraday move suggests the market views these results as a positive surprise, but the full context — guidance, competitive commentary, and geographic breakdowns — will emerge from the accompanying earnings call and full financial statements.

---

Disclaimer

This report is a news and informational summary based on data extracted directly from DexCom's SEC filing and is intended for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell any security, or a formal equity research recommendation. No rating or price target is issued or implied herein. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decision. All financial figures cited are sourced exclusively from the structured XBRL data associated with the referenced SEC filing.

Existing Coverage

StockWatch has full coverage on DXCM, published 2026-10-21. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-10-29. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000193/dxcm-20261029.htm